Argenica Therapeutics Strengthens Regulatory Team with Key Appointment

An update from Argenica Therapeutics Ltd ( (AU:AGN) ) is now available.

Argenica Therapeutics has appointed Sharon Hanegraaf as Vice President of Regulatory Affairs to lead the company’s regulatory activities, including submissions to the FDA and other global regulatory bodies. This strategic hire is expected to bolster Argenica’s efforts to advance its lead candidate, ARG-007, into later-stage clinical trials for acute ischaemic stroke, enhancing its clinical program and potentially improving patient outcomes in neurological conditions.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following strokes and other neurological conditions. Their lead candidate, ARG-007, has shown promise in pre-clinical models for stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy, and is currently undergoing Phase 2 clinical trials for acute ischaemic stroke.

Average Trading Volume: 89,814

Technical Sentiment Signal: Sell

See more data about AGN stock on TipRanks’ Stock Analysis page.